Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on …
J Romano, A Kashuba, S Becker… - AIDS research and …, 2013 - liebertpub.com
Thirty years after its beginning, the HIV/AIDS epidemic is still raging around the world.
According to UNAIDS, in 2011 alone 1.7 M deaths were attributable to AIDS, and 2.5 M …
According to UNAIDS, in 2011 alone 1.7 M deaths were attributable to AIDS, and 2.5 M …
Dolutegravir pharmacokinetics in the genital tract and colorectum of HIV-negative men after single and multiple dosing
BN Greener, KB Patterson, HMA Prince… - JAIDS Journal of …, 2013 - journals.lww.com
Objectives: To describe first-dose and steady state pharmacokinetics (PKs) of dolutegravir
(DTG) in blood plasma (BP), seminal fluid (SF), colorectal tissue (RT), and rectal mucosal …
(DTG) in blood plasma (BP), seminal fluid (SF), colorectal tissue (RT), and rectal mucosal …
Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure
KB Patterson, HA Prince, T Stevens, NJ Shaheen… - Aids, 2013 - journals.lww.com
Objective: To investigate the concentration of the integrase strand inhibitor raltegravir (RAL)
throughout gastrointestinal (GI) tissue, especially gut-associated lymphoid tissue (GALT), as …
throughout gastrointestinal (GI) tissue, especially gut-associated lymphoid tissue (GALT), as …
[HTML][HTML] HIV PrEP trials: the road to success
The global HIV epidemic cannot be controlled by current treatment or prevention strategies.
Pre-exposure prophylaxis (PrEP) using antiretrovirals is a promising approach to curbing the …
Pre-exposure prophylaxis (PrEP) using antiretrovirals is a promising approach to curbing the …
Changes in HIV-1 subtypes B and C genital tract RNA in women and men after initiation of antiretroviral therapy
SA Fiscus, S Cu-Uvin, AT Eshete… - Clinical infectious …, 2013 - academic.oup.com
Background. Combination antiretroviral therapy (cART) reduces genital tract human
immunodeficiency virus type 1 (HIV-1) load and reduces the risk of sexual transmission, but …
immunodeficiency virus type 1 (HIV-1) load and reduces the risk of sexual transmission, but …
HIV pre-exposure prophylaxis trials: the road to success.
MR Nicol, JL Adams, ADM Kashuba - 2013 - cabidigitallibrary.org
The global HIV epidemic cannot be controlled by current treatment or prevention strategies.
Pre-exposure prophylaxis (PrEP) using antiretrovirals is a promising approach to curbing the …
Pre-exposure prophylaxis (PrEP) using antiretrovirals is a promising approach to curbing the …